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Abstract
Background: The incidence of lung adenocarcinoma (LUAD) is increasing worldwide with different prognosis
even in early-stage patients. We aimed to identify a prognostic panel with multiple DNA methylation biomarkers
to predict survival in early-stage LUAD patients of different racial groups.
Methods: The methylation array, pyrosequencing methylation assay, Cox regression and Kaplan-Meier analyses
were conducted to build the risk score equations of selected probes in a training cohort of 69 Asian LUAD patients.
The risk score model was verified in another cohort of 299 Caucasian LUAD patients in The Cancer Genome Atlas
(TCGA) database.
Results: We performed a Cox regression analysis, in which the regression coefficients were obtained for eight
probes corresponding to eight genes (AGTRL1, ALDH1A3, BDKRB1, CTSE, EFNA2, NFAM1, SEMA4A and TMEM129).
The risk score was derived from sum of each methylated probes multiplied by its corresponding coefficient.
Patients with the risk score greater than the median value showed poorer overall survival compared with other
patients (p = 0.007). Such a risk score significantly predicted patients showing poor survival in TCGA cohort
(p = 0.036). A multivariate analysis was further performed to demonstrate that the eight-probe panel association with
poor outcome in early-stage LUAD patients remained significant even after adjusting for different clinical variables
including staging parameters (hazard ratio, 2.03; p = 0.039).
Conclusions: We established a proof-of-concept prognostic panel consisting of eight-probe signature to predict
survival of early-stage LUAD patients of Asian and Caucasian populations.
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Background
Lung cancer is the leading cause of cancer-related deaths
with an increasing incidence of lung adenocarcinoma
(LUAD) subtype worldwide [1]. Prognosis may vary in
patients with the same stage tumor because cancer is
characterized by genetic, epigenetic, and phenotypic
changes that result in a tremendous variability in clinical
behavior [2, 3]. Therefore, the development of additional
molecular markers for survival prediction of LUAD is
required.
DNA methylation, which usually occurs in CpG dinu-
cleotides, is a major epigenetic modification in mamma-
lian genome [4–6]. High-throughput methylation arrays
are now available to determine DNA methylation levels
of thousands of CpG sites, simultaneously [7–9]. This
technology enables large-scale DNA methylation analysis
to identify informative DNA methylation biomarkers in
lung cancer [7, 10–16]. Many reports have demonstrated
that each cancer subtypes such as lung adenocarcinoma
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and squamous cell carcinoma has its own methylation
signature [12, 13, 15, 16].
Therefore, in the current study we focus on the devel-
opment of survival predictors in early-stage LUAD
patients by performing genome-wide methylation ana-
lysis and pyrosequencing quantitative methylation assay
to select eight DNA methylation probes in a training
cohort of 69 patients recruited in Taipei Veterans
General Hospital (TVGH). We also included certain
clinical parameters that are known to affect prognosis
[2, 3, 17–19] along with the selected eight-probe
panel to the Cox regression analysis. The relevance of
our finding has been validated in a cohort of 299
patients as part of The Cancer Genome Atlas (TCGA)
project.
Methods
Patients and tissue samples
A total of 69 surgically resected LUAD patients in early
stage (stages I and II) were recruited from Taipei
Veterans General Hospital (TVGH), after obtaining
appropriate institutional review board permission (#98-
03-18A) and informed consent from the patients. These
LUAD patients with checked clinical data and suffi-
cient amount of DNA available for successful
genome-wide methylation and pyrosequencing quanti-
tative methylation assays were defined as a training
cohort. A validation cohort of 299 LUAD patients
with clinical follow-up data and methylation micro-
array data available from TCGA were collected. The
mean follow-up period for training cohort was
82 months (range 9–157 months) and for validation
cohort was 37 months (range 12–242 months). The
end of the follow-up in TVGH was defined as January
2016 and TCGA as April 2015. Patients with clinico-
pathological characteristics are shown in Table 1.
Genomic DNA extraction and sodium bisulfite conversion
Genomic DNA from primary tumor tissue samples of 69
patients from TVGH were extracted using proteinase K
digestion and phenol-chloroform extraction. A total of
1 μg genomic DNA was used for bisulfite conversion
using the EpiTect Bisulfite kit (Qiagen, Duesseldorf,
Germany) according to the manufacturer’s protocols.
The genome-wide methylation analysis platform
The Illumina Infinium HumanMethylation27 BeadChip
(27,578 CpG dinucleotides for 14,495 genes) was
adapted for DNA methylation detection according to
manufacturer’s manual. DNA methylation levels were
reported as β-values by calculating the ratio of inten-
sities between locus-specific methylated and unmethy-
lated bead-bound probes. The β-value is a continuous
variable, ranging from 0 (unmethylated) to 1 (fully
methylated). The methylation array data can be viewed
online under GEO accession number GSE83845.
Pyrosequencing assay
To quantify cytosine methylation in individual CpG sites
of candidate methylation probes identified by methyla-
tion array, bisulfite-converted DNA was analyzed using a
pyrosequencing system (PyroMark Q24, Qiagen, Hilden,
Germany). Specific pyrosequencing primer and PCR pri-
mer were designed for “target” CpG sites in the probes
to be analyzed. Pyrosequencing was carried out in ac-
cordance with the manufacturer’s protocol (Qiagen).
The target CpG sites were evaluated by converting the
resulting pyrograms to numerical values for peak
Table 1 Characteristics of the lung adenocarcinoma patients
included in the current study
Cohort TVGHa (%) TCGAa (%)
N = 69 (100 %) N = 299 (100 %)
Age
< 65 year-old 25 (36.2 %) 124 (41.5 %)
≥ 65 year-old 44 (63.8 %) 166 (55.5 %)
Stage
Stage IA 13 (18.8 %) 113 (37.8 %)
Stage IB 42 (60.9 %) 104 (34.8 %)
Stage IIA 4 (5.8 %) 32 (10.7 %)
Stage IIB 10 (14.5 %) 50 (16.7 %)
T stage
Stage 1 16 (23.2 %) 122 (40.8 %)
Stage 2 51 (73.9 %) 159 (53.2 %)
Stage 3 2 (2.9 %) 18 (6.0 %)
N stage
N0 56 (81.2 %) 236 (78.9 %)
≥ N1 12 (17.4 %) 57 (19.1 %)
M stage
M0 69 (100 %) 299 (100 %)
≥M1 0 (0.0 %) 0 (0.0 %)
Surgery
Lobectomy 60 (87.0 %) -b
Wedge resection 8 (11.6 %) -b
Segmentectomy 1 (1.4 %) -b
Chemotherapy
No 51 (73.9 %) -b
Yes 15 (21.7 %) -b
TKI treatment
No 62 (89.9 %) -b
Yes 6 (8.7 %) -b
aTVGH: Taipei Veterans General Hospital; TCGA: The Cancer Genome Atlas
bInformation was not available for patients from TCGA
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heights. Primer sequences are listed in Additional file 1:
Table S1, and the genomic map of the detected CpG
sites are shown in Additional file 1: Figure S1.
Data processing and statistical analysis
Receiver operating characteristic (ROC) curve analysis
was performed to determine the accuracy of the estab-
lished CpG panel [area under the curve (AUC), sensitiv-
ity, and specificity]. The univariate and multivariate Cox
regression analyses were conducted to explore the rela-
tionship between patient survival and several explana-
tory variables for defining the hazard ratio (HR) and
confidence intervals (CI) of cancer death risk of variables
using the Statistical Package for the Social Sciences ver-
sion 17.0 (SPSS Inc., Headquarters Chicago, IL, USA).
Overall survival curves were calculated according to the
Kaplan-Meier method. p < 0.05 was considered statisti-
cally significant.
Results
Marker discovery in genome-scale DNA methylation
dataset
In the marker selection phase of this study, we collected
surgically dissected tumors of 69 early-stage LUAD
patients from TVGH to form a training cohort for
genome-wide methylation array analysis using Illumina
Infinium HumanMethylation27 BeadChip. Procedures
were performed as described below and shown in Fig. 1.
First, we obtained 9384 qualified probes after removing
potentially problematic probes, probes containing SNP,
repeat sequencing, probes not in CpG island, probes in
the X-chromosome and the non-differential probes with
β-value greater than 0.9 or less than 0.1 in all samples
after methylation analysis. Second, we selected 2815 in-
formative probes with large variance of βtumor (top-30 %
ranked) among the patients. Third, for each probe, a
supervised principal components (Superpc) analysis [20]
was applied to compare the survival distributions be-
tween patients with methylation levels above and below
the mean level of all tumor tissues analyzed; 100 probes
were chosen based on these tests. Fourth, since pyrose-
quencing assay is a highly sensitive method for detection
of DNA methylation [12, 17, 21], we performed pyrose-
quencing methylation analyses. Of these probes, pyrose-
quencing was successfully designed and performed for
34 probes. A high concordance in quantifying the CpG
methylation level was observed between DNA methyla-
tion array and pyrosequencing assay (Fig. 2). Fifth, eight
specific candidate probes corresponding to eight genes
showed significant correlation with survival by univariate
Cox regression, including Angiotensin II receptor-like 1
(AGTRL1), Aldehyde dehydrogenase 1 family member A3
(ALDH1A3), Bradykinin receptor B1 (BDKRB1), Cathepsin
E (CTSE), Ephrin A2 (EFNA2), NFAT activating protein
with ITAM motif 1 (NFAM1), Semaphorin 4A (SEMA4A),
and Transmembrane protein 129 (TMEM129) (Table 2).
Sixth, we applied receiver operating characteristic (ROC)
curve analysis to determine the diagnostic sensitivity and
specificity of eight-probe panel in the validation cohort of
Fig. 1 Flowchart of the probe selection and clinical validation
procedures. Six steps were used to select the eight methylation
gene probes from the methylation array in the training cohort of 69
LUAD patients from TVGH. The Kaplan-Meier survival analysis with
the regression coefficients of eight probes was first performed to
confirm the survival prediction of risk score calculation. The multivariate
Cox regression was then performed to validate clinical performance of
the eight-probe panel after adjusting for different clinical variables. The
Kaplan-Meier survival analysis and multivariate Cox regression method
were also performed in the validation cohort of 299 LUAD patients
from TCGA database
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Fig. 2 Correlation of methylation level between Illumina array and pyrosequencing method of top 34 methylated probes in early-stage LUAD
patients. Dot-plot analyses show a high concordance of methylation level between pyrosequencing DNA methylation assay (Y-axis: %)
and Illumina genome-wide methylation assay (X-axis: β value) and of 34 methylated probes. An average correlation coefficient was 0.81
(R = 0.81) among the probes
Table 2 Univariate Cox model for 34 probes in the training cohort of LUAD by pyrosequencing methylation assay
No. probes IDa gene symbol p valueb No. probes IDa gene symbol p valueb
1 cg04878152 AGTR1 0.680 18 cg05973262 NOTCH4 0.126
2 cg25072179 AGTRL1c 0.001 19 cg16678925 OR1A2 0.164
3 cg27652350 ALDH1A3c 0.007 20 cg10046892 PAQR6 0.386
4 cg16787352 ANKRD9 0.223 21 cg11428724 PAX7 0.444
5 cg10528989 BDKRB1c 0.021 22 cg01431114 PDE10A 0.356
6 cg16077929 CDKL1 0.373 23 cg13645078 PHLDA3 0.877
7 cg21478437 CTSEc 0.007 24 cg24427660 PNPLA2 0.443
8 cg11885098 EFNA2c 0.002 25 cg09635067 RAB7L1 0.679
9 cg03158400 FAM3B 0.219 26 cg10559803 RALGPS2 0.175
10 cg00626466 GNS 0.384 27 cg15983538 SEMA4Ac 0.030
11 cg13228642 IER5 0.275 28 cg04275881 SLAMF8 0.103
12 cg01226811 KCNJ8 0.564 29 cg16415058 SORCS1 0.265
13 cg17536532 KIAA0649 0.334 30 cg15789095 SPOCD1 0.811
14 cg10150813 KIAA0746 0.672 31 cg22594309 SYT2 0.944
15 cg12610744 KRT4 0.061 32 cg21505886 TMEM129c 0.004
16 cg22820108 NCOR2 0.546 33 cg08108311 WNK4 0.296
17 cg17568996 NFAM1c 0.002 34 cg01184522 ZNF496 0.560
aProbes ID is the CpG number of designated probe used in Illumina Human Methylation27 Bead Chip
bUnivariate Cox regression
cGenes in bold font indicated statistical significance (p < 0.05) thus were selected for further analyses
Kuo et al. Journal of Biomedical Science  (2016) 23:58 Page 4 of 10
TVGH patients. Finally, Kaplan-Meier method and multi-
variate Cox regression analyses were performed for the
eight-probe panel in the TVGH patients and validated in
299 early-stage LUAD patients from TCGA datasets (as
described below).
Sensitivity and specificity of the eight selected probes by
ROC analysis
We examined the sensitivity and specificity of the eight
selected probes by ROC curve analysis in the training
cohort of 69 early-stage LUAD patients from TVGH.
The area under the curve (AUC) of eight-probe together
was 0.802 (Fig. 3a), indicating that the eight-probe signa-
ture showed good sensitivity and specificity in the ROC
analysis. To assess the accuracy of the prognostic pre-
dictor panel, ROC curve analysis was performed on
another randomly selected eight probes from the top 34
candidate probes. The AUC was 0.602 (Fig. 3b), suggest-
ing a stronger prediction power of the specifically se-
lected eight probes than the randomly selected probes.
Thus, we defined this eight-probe signature as the prog-
nostic predictor panel of early-stage LUAD.
The risk score calculation and survival prediction of the
eight-probe panel by Kaplan-Meier method
In the clinical validation phase, we first built the risk
score for the eight selected methylation probes using the
multivariate Cox regression analysis in the TVGH train-
ing cohort of 69 early-stage LUAD patients. These DNA
methylation probe covariates were weighted by the
regression coefficients to calculate the coefficient and
hazard ratio for each patient. The risk score for each
patient was derived from sum of methylation value of
each probe multiplied by the corresponding coeffi-
cient, as following equation: risk score = AGTRL1
methylation value × (-0.015) + ALDH1A3 methylation
value × (-0.023) + BDKRB1 methylation value × (-0.034) +
CTSE methylation value × (0.022) + EFNA2 methylation
value × (0.010) +NFAM1 methylation value × (-0.017) +
SEMA4A methylation value × (-0.012) +TMEM129 methy-
lation value × (-0.006). Example of risk score calculation
for two patients is shown in Additional file 1: Figure S2.
Furthermore, we used the risk score calculation ran-
ging from -1.03 to -4.95 to classify patients into two
groups by median value of -2.63 in the TVGH training
cohort of 69 early-stage LUAD patients (upper panel,
Fig. 4a). The Kaplan-Meier overall survival analysis was
performed to show the relative survival in each of the
two groups identified by the risk score calculation (mid-
dle panel, Fig. 4a). Patients with high risk score indeed
had a short median survival time (MST) of 58.9 months
compared with other patients. The difference in the
MST and 95 % confidence interval (CI) between the two
groups was highly significant (lower panel, Fig. 4a).
Therefore, the median risk score (as -2.63) was chosen
as the cutoff value for survival prediction in the TVGH
cohort.
We further applied our risk score model to determine
whether our finding could be validated in another cohort
of 299 early-stage LUAD patients whose follow-up data
were available in TCGA project, and methylation level
was also determined by the Infinium Methylation array.
Fig. 3 ROC curves of the prognostic predictor panel in the training cohort from TVGH. Sensitivity is indicated in the Y-axis, whereas 1 substrated
by specificity (1-Specificity) is indicated in the X-axis. a The area under the curve (AUC) of ROC analysis for the eight selected probes
panel. b The AUC of ROC analysis for the eight randomly selected genes
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The risk score calculated with the median value (as 0.47)
classified the 299 TCGA patients into two groups (upper
panel, Fig. 4b). Such a calculation predicted a subset of
patient with a high risk score showing poorer survival
with MST of 50.9 months (middle panel, Fig. 4b) with
statistical significance (lower panel, Fig. 4b). These
results indicated that the prognostic predictor panel
consisting of the selected eight-probe showed a strong
prediction value in the TCGA validation cohort.
Univariate and multivariate Cox regression analysis of the
eight-probe panel
To determine whether the eight-probe panel is an inde-
pendent variable associated with poor survival of early-
stage LUAD patients, we performed the univariate and
multivariate Cox regression model in both TVGH and
TCGA cohorts. The univariate Cox regression analysis
revealed that patients with risk score > median of the
eight-probe panel, stage IIA, stage IIB, or lymph node
metastases had poor outcome (p = 0.009, HR = 2.37,
95 % CI = 1.24–4.53 for risk score > median of the
eight-probe panel; Table 3). Notably, multivariate Cox
regression analysis showed that the eight-probe panel
correlated with a relative risk of death of 2.03 (p =
0.039), even after adjusting for the tumor staging and
metastasis status (Table 3), suggesting that the eight-
probe panel was an independent risk factor of poor
outcome.
To further define the prognostic effects of the eight-
probe panel in early-stage LUAD patients, univariate
and multivariate Cox regression analyses were per-
formed in the TCGA validation cohort of 299 early-stage
LUAD patients. Univariate Cox regression analysis re-
vealed that patients with the risk score > median of the
eight-probe panel had poor outcome, with a relative risk
of death of 1.66 (p = 0.038) (Table 3). However, the
eight-probe panel showed a borderline significance by
the multivariate analysis in the TCGA cohort.
Fig. 4 Survival risk score prediction based on the selected eight-probe in LUAD patients. a The risk score was used to classify 69 TVGH patients in
the training cohort into two groups by median (as -2.63) (upper). The Kaplan-Meier overall survival analysis was performed to show the relative
median survival time (MST) in two groups identified by the risk score calculation (middle). The 95 % confidence interval of survival time
and p values of various methods are shown as indicated (lower). b The risk score, MST, and p values were analyzed in the validation
cohort of 299 LUAD patients from TCGA database
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Discussion
The incidence of LUAD is increasing worldwide [1].
Patients with the same stage of lung cancer may have
different prognosis [22]. Development of prognostic
markers is especially important in the patients with
early-stage lung cancer, in whom clinical oncologists
need selection factors to decide whether adjuvant
therapy is necessary. In the present study, we develop
a prognostic predictor panel for early-stage LUAD pa-
tients. This panel consists of eight DNA methylation
probes corresponding to eight specific genes, includ-
ing AGTRL1, ALDH1A3, BDKRB1, CTSE, EFNA2,
NFAM1, SEMA4A, and TMEM129. The risk score
calculated using the eight-probe panel served as an
independent prognosis biomarker by Cox regression
model and the multivariate analysis in our recruited
patients. Therefore, the risk scores calculated from
this eight-probe panel are valuable biomarkers for
prognostic evaluation for early-stage LUAD patients
to be tested in other cohorts.
Table 3 Univariate and multivariate Cox regression analyses of risk factors for cancer-related death in early-stage LUAD patients
TVGH (N = 69)a TCGA (N = 299)a
Characteristics Univariate analysis Multivariate analysisc Univariate analysis Multivariate analysisc
HR (95 % CI)b p-valueb HR (95 % CI)b p-valueb HR (95 % CI)b p-valueb HR (95 % CI)b p-valueb
Eight-probe panel
Risk < Median 1.00 1.00 1.00 1.00
Risk > Median 2.37 (1.24–4.53) 0.009 2.03 (1.04–3.98) 0.039 1.66 (1.03–2.66) 0.038 1.57 (0.96–2.57) 0.073
Gender
Male 1.00 - 1.00 -
Female 1.43 (0.71–2.88) 0.321 - - 0.78 (0.49–1.26) 0.315 - -
Stage
Stage IA 1.00 1.00 1.00 1.00
Stage IB 2.13 (0.73–6.16) 0.164 2.01 (0.69–5.86) 0.199 1.15 (0.63–2.11) 0.642 1.17 (0.63–2.16) 0.616
Stage IIA 8.76 (2.10–36.53) 0.003 5.79 (0.72–46.58) 0.099 2.17 (0.98–4.81) 0.057 0.85 (0.21–3.38) 0.817
Stage IIB 6.11 (1.81–20.64) 0.003 3.65 (0.70–18.92) 0.124 2.04 (1.07–3.91) 0.031 0.91 (0.26–3.15) 0.885
T stage
Stage 1–2 1.00 - 1.00 -
Stage 3–4 2.22 (0.53–9.28) 0.277 - - 0.62 (0.15–2.53) 0.502 - -
T stage
Stage 1 1.00 - 1.00 -
Stage 2 1.23 (0.56–2.68) 0.613 - 1.28 (0.77–2.12) 0.338 -
Stage 3 2.59 (0.54–12.32) 0.232 - - 0.72 (0.17–3.07) 0.657 - -
N stage
N0 1.00 1.00 1.00 1.00
≥ N1 3.95 (1.88–8.30) 0.001 1.54 (0.35–6.91) 0.571 2.27 (1.38–3.73) 0.001 2.51 (0.74–8.43) 0.138
Chemotherapy
No 1.00 -
Yes 1.84 (0.92–3.69) 0.084 - -
TKI treatment
No 1.00 -
Yes 2.03 (0.79–5.26) 0.144 - -
Surgery
Lobectomy 1.00 -
Wedge resection 1.35 (0.53–3.45) 0.536 -
Segmentectomy 2.98 (0.40–22.31) 0.288 - -
aTVGH: Taipei Veterans General Hospital; TCGA: The Cancer Genome Atlas
bCI, confidence interval; HR, hazard ratio. Bold values indicate statistical significance (p < 0.05)
cThe variables without significant HR in the univariate analysis were not included in the multivariate analysis
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Recently, Heller et al. identified a total of 12 genes
that were differentially methylated in tumors com-
pared with surrounding tissues in stage I, II or III
Caucasian non-small cell lung cancer patients.
Among the 12 genes, only the methylation patterns
of HOXA2 and HOXA10 were independent prognos-
tic factors in lung squamous cell carcinoma patients
[15]. In addition, Esteller and the associates used
methylation array to establish methylation profiles of
stage I Caucasian non-small cell lung cancer and
identified that methylation of two or more genes in
HIST1H4F, PCDHGB6, NPBWR1, ALX1, and HOXA9
correlated with an increased risk of cancer recur-
rence [16]. Interestingly, HOXA9 promoter methyla-
tion was associated with high risk in stage I LUAD
patients of two independently cohorts by another
study [23]. To date, all studies that have been exe-
cuted in an attempt to find markers for clinical use
do not include patients from different racial groups.
In our study, the prognostic predictor panel compris-
ing eight DNA methylation biomarkers was an inde-
pendent risk factor of poor outcome in Asian LUAD
patients. We further applied our risk score model to
determine whether our finding could be validated in
another cohort of 299 early-stage LUAD patients
whose follow-up data were available in TCGA pro-
ject. The new coefficient and hazard ratio were de-
fined according to the methylation value of the eight
probes given in TCGA database of these patients.
The Kaplan-Meier overall survival analysis showed
that TCGA patients with risk score greater than me-
dian value had a shorter MST compared with other
patients (Fig. 4b). However, the result of multivariate
Cox regression was only close to significance in the
Caucasian LUAD patients (Table 3). One of the limi-
tations of the current TCGA study is that we are un-
able to acquire the data on treatment or surgery
performed on the TCGA patients (Table 1). We
believe that these results could be improved after
including data from more patients when they are
available in TCGA dataset or by validating in other
cohorts of Caucasian LUAD patients.
The identification of the eight probes that can pre-
dict the clinical outcome in patients may reveal
causes of the cancer development and tumorigenesis.
For example, Angiotensin II receptor-like 1 (AGTRL1)
and Bradykinin receptor B1 (BDKRB1) are G-protein-
coupled receptors (GPCRs). GPCRs, which represent
by far the largest family of cell-surface molecules in-
volved in signal transduction, have recently emerged
as crucial players in tumor growth and metastasis
[24]. AGTRL1 is Apelin receptor. Apelin is an angio-
genic factor secreted by tumor cells in order to pro-
mote the formation of new vessels necessary for
tumor growth [25]. In addition, crosstalk between
BDKRB1 and EGFR has been shown to maintain
tumor growth in the breast cancer [26]. Aldehyde de-
hydrogenase 1 family, member A3 (ALDH1A3) is the
retinoic acid biosynthesis enzyme, and plays a major
role in the detoxification of aldehydes generated by
alcohol metabolism and lipid peroxidation. Promoter
hypermethylation of ALDH1A3 has been reported to
be a prognostic marker for lung cancer, gastric cancer,
and invasive bladder cancer [27–30]. Cathepsin E
(CTSE) prevents tumor growth and metastasis by
catalyzing the proteolytic release of soluble trail from
tumor cell surface [31]. Ephrin A2 (EFNA2), which
belongs to ephrins family, regulates cell adhesion,
motility, survival, proliferation, and differentiation.
Semaphorins 4A (SEMA4A) suppresses endothelial
cell migration and proliferation in vitro and angiogen-
esis in vivo mediated by vascular endothelial growth
factor [32]. Further characterization of the probes
validated in our panel could help to dissect the mech-
anism of LUAD tumorigenesis and progression.
The advantages of our prognostic predictor panel
are as follows. First, the methylation level of the eight
probes could be analyzed by DNA methylation array
or pyrosequencing in patients. Second, the stepwise
multivariate Cox regression analysis, in which the co-
efficients were obtained for the selected eight probes,
could generate the risk score equations specifically for
the cohort of patients to be tested. Third, any newly
recruited patients could be assigned into risk groups
once the risk score equations are determined. There-
fore, the prognostic predictor panel could calculate
the risk score not only in the Asian but also in the
Caucasian LUAD patients. However, some technical
limitations such as sample collection and preprocess-
ing as well as experimental procedures of DNA
methylation array or pyrosequencing assay need to be
controlled to avoid batch effects. In addition, clinical
variables such as adjuvant therapy and surgical
methods may affect outcome prediction. Large-scale,
multicenter and prospective studies are necessary to
validate our risk score model in early-stage LUAD
patients.
Conclusions
Our study provides a proof-of-concept prognostic pre-
diction panel consisting of eight methylated probes
that are closely associated with survival in the early-
stage LUAD patients. This prediction panel could be
useful in stratifying patients according to the Cox-
model and risk score before further treatment for
early-stage LUAD patients who in dire need of inten-
sive care.
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Additional file
Additional file 1: Table S1. The primers used for pyrosequencing
analysisa. Figure S1. The genomic maps of the selected genes and CpG
sites in DNA methylation biomarker studies. cg_number is the CpG
number of selected probes from methylation array. TSS: transcription
start site. The black arrows (▼) indicate the detected CpG sites in
Infinium array and the white arrows (△) indicate the sites in pyrosequencing.
The nucleotides relative to TSS are shown. Figure S2. Risk score calculation
and risk group assignment of two example patients. A Coefficient (coef) of
genes and clinical variables were established by multivariate Cox
regression model. A patient’s risk score was derived from sum of
each probe methylation level multiplied by its corresponding
coefficient. The equations used are as follows: Risk score = AGTRL1
methylation value × (-0.015) + ALDH1A3 methylation value × (-0.023) +
BDKRB1 methylation value × (-0.034) + CTSE methylation value × (0.022)
+ EFNA2 methylation value × (0.010) + NFAM1 methylation value ×
(-0.017) + SEMA4A methylation value × (-0.012) + TMEM129 methylation
value × (-0.006). B The risk score ranging from -1.03 to 4.95 was used
to classify patients into two groups by the median value (as -2.63).
Patient A with risk score of -1.0318 was assigned to the high risk
group and patient B with -4.4262 was assigned to the low risk
group. (DOCX 360 kb)
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